Were Bruce Booth’s KYMR share sales made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the sales were made under a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X and Atlas Venture Opportunity Fund I on December 11, 2025 , indicating the transactions were pre-arranged rather than discretionary trades.

Atlas Venture funds linked to Kymera (NASDAQ: KYMR) sell 31,283 shares under plan

Q: What insider transactions did Kymera Therapeutics (KYMR) report for Bruce Booth?

Kymera Therapeutics reported that director Bruce Booth had indirect open-market sales totaling 31,283 shares of common stock on June 29, 2026. The transactions were executed through Atlas Venture funds under a pre-arranged Rule 10b5-1 trading plan .

Q: At what prices were the KYMR shares sold in Bruce Booth’s recent Form 4?

The reported Kymera Therapeutics share sales used weighted-average prices between approximately $108.03 and $111.63 per share. Individual trades occurred in multiple transactions within those ranges, as detailed in the filing’s footnotes describing the pricing.

Q: Does Bruce Booth directly own the Kymera Therapeutics shares sold in this Form 4?

No. The filing explains the shares are held by Atlas Venture funds , and Booth is a member of their general partner entities. He disclaims Section 16 beneficial ownership of those securities except to the extent of any pecuniary interest.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Kymera Therapeutics director Bruce Booth reported indirect open-market sales of a total of 31,283 shares of Kymera common stock on June 29, 2026. The trades, executed at weighted-average prices between about $108 and $111 per share, were made under a pre-arranged Rule 10b5-1 trading plan by Atlas Venture funds that hold the shares, for which Booth disclaims beneficial ownership beyond any pecuniary interest.

Insider Trade Summary 10b5-1

Net Seller: 31,283 shares ($3,424,800)

Net Sell 8 txns

Insider Booth Bruce

Role null

Sold 31,283 shs ($3.42M)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,658	$108.28	$1.15M
Sale	Common Stock	7,833	$109.75	$860K
Sale	Common Stock	7,602	$110.67	$841K
Sale	Common Stock	907	$111.20	$101K
Sale	Common Stock	1,688	$108.28	$183K
Sale	Common Stock	1,239	$109.75	$136K
Sale	Common Stock	1,199	$110.67	$133K
Sale	Common Stock	157	$111.20	$17K

Holdings After Transaction: Common Stock — 2,402,089 shares (Indirect, See footnote)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (6). These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

Key Figures

Shares sold: 31,283 shares Price range low: $108.0326/share Price range high: $111.63/share +3 more

6 metrics

Shares sold 31,283 shares Total indirect open-market sales on June 29, 2026

Price range low $108.0326/share Lowest weighted-average sale price reported in footnotes

Price range high $111.63/share Highest weighted-average sale price reported in footnotes

10b5-1 plan adoption date December 11, 2025 Rule 10b5-1 trading plan for Atlas Venture funds

Single trade size example 10,658 shares One reported sale at $108.2800 per share

Another trade size example 7,833 shares One reported sale at $109.7500 per share

Key Terms

Rule 10b5-1 trading plan, weighted average price, Section 16 beneficial ownership, pecuniary interest, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Section 16 beneficial ownership regulatory

"The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X"

pecuniary interest financial

"disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any"

indirect ownership financial

"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF")"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 05:32 PM Accepted by SEC EDGAR 06/30/2026 - 05:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Bruce

(Last)

(First)

(Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, FLOOR 4

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/29/2026		S⁽¹⁾		10,658	D	$108.28⁽²⁾	2,402,089	I	See footnote⁽³⁾
Common Stock	06/29/2026		S⁽¹⁾		7,833	D	$109.75⁽⁴⁾	2,394,256	I	See footnote⁽³⁾
Common Stock	06/29/2026		S⁽¹⁾		7,602	D	$110.67⁽⁵⁾	2,386,654	I	See footnote⁽³⁾
Common Stock	06/29/2026		S⁽¹⁾		907	D	$111.2⁽⁶⁾	2,385,747	I	See footnote⁽³⁾
Common Stock	06/29/2026		S⁽¹⁾		1,688	D	$108.28⁽²⁾	464,389	I	See footnote⁽⁷⁾
Common Stock	06/29/2026		S⁽¹⁾		1,239	D	$109.75⁽⁴⁾	463,150	I	See footnote⁽⁷⁾
Common Stock	06/29/2026		S⁽¹⁾		1,199	D	$110.67⁽⁵⁾	461,951	I	See footnote⁽⁷⁾
Common Stock	06/29/2026		S⁽¹⁾		157	D	$111.2⁽⁶⁾	461,794	I	See footnote⁽⁷⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (6).

3. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive.

7. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

Remarks:

Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the second of two filings.

	/s/ Ommer Chohan, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Kymera Therapeutics (KYMR) report for Bruce Booth?

Kymera Therapeutics reported that director Bruce Booth had indirect open-market sales totaling 31,283 shares of common stock on June 29, 2026. The transactions were executed through Atlas Venture funds under a pre-arranged Rule 10b5-1 trading plan.

At what prices were the KYMR shares sold in Bruce Booth’s recent Form 4?

The reported Kymera Therapeutics share sales used weighted-average prices between approximately $108.03 and $111.63 per share. Individual trades occurred in multiple transactions within those ranges, as detailed in the filing’s footnotes describing the pricing.

Does Bruce Booth directly own the Kymera Therapeutics shares sold in this Form 4?

No. The filing explains the shares are held by Atlas Venture funds, and Booth is a member of their general partner entities. He disclaims Section 16 beneficial ownership of those securities except to the extent of any pecuniary interest.

How many Kymera Therapeutics shares were sold indirectly by Atlas Venture funds?

According to the Form 4, entities associated with Atlas Venture conducted indirect open-market sales of 31,283 Kymera Therapeutics shares. These sales were broken into multiple transactions, each reported with share amounts and weighted-average prices within specified ranges.